BridgeBio Pharma to merge with Eidos Therapeutics in a $175m deal.

BridgeBio Pharma, a company focused on genetic diseases, agreed to merge with Eidos Therapeutics, a clinical-stage biotech company, in a $175m deal. "With the completion of screening in the Phase 3 ATTRibute-CM study of acoramidis and expected enrollment of more than 600 participants, now is the time to begin laying the groundwork for a global launch. This transaction removes the operational complexity of the current ownership structure and allows us to fully unlock the potential of this investigational medicine for patients and investors. Bringing Eidos fully back to BridgeBio positions us to invest in all opportunities around acoramidis, including subsequent studies to potentially broaden the evidence for its usage, and accelerate its commercial development using BridgeBio’s established infrastructure. We are excited to welcome acoramidis back into an ecosystem where cutting-edge science is being done across inherited diseases and targeted oncology," Neil Kumar, BridgeBio Founder and CEO.